Black Diamond Therapeutics Inc (BDTX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$2.12+0.95%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · BDTX
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | |
|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||
| Revenues | — | 70.0 | — | — | — | — | 0.0 | 0.0 |
| Operating Expenses & Income | ||||||||
| R&D Expenses | 28.1 | 33.6 | 51.3 | 59.4 | 64.4 | 96.8 | 48.2 | 21.8 |
| Operating Income | (51.9) | 12.5 | (78.8) | (86.5) | (92.8) | (126.9) | (69.6) | (29.3) |
| Earnings from Continuing Operations | ||||||||
| Interest Expense | — | — | — | — | — | 0.0 | 0.0 | — |
| Interest & Investment Income | 4.3 | 4.1 | 2.2 | 1.9 | 2.0 | 3.5 | 4.0 | 0.5 |
| Net Interest Expenses | — | — | — | — | — | (3.5) | (4.0) | — |
| Other Non-Operating Income / Expenses | 9.3 | 9.8 | 9.1 | 4.0 | 3.9 | 1.3 | 2.3 | (5.9) |
| Asset Writedown | — | 7.3 | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Income | ||||||||
| Net Income | 22,302.1 | 22.4 | (69.7) | (82.4) | (91.2) | (125.6) | (67.3) | (35.3) |
| Per Share | ||||||||
| Basic EPS | 388.76 | 0.39 | (1.27) | (1.88) | (2.52) | (3.47) | (2.05) | — |
| Diluted EPS | 388.76 | 0.39 | (1.27) | (1.88) | (2.52) | (3.47) | (2.05) | — |
| Basic Weighted Avg Shares | 57.4 | 56.9 | 55.0 | 44.0 | 36.3 | 36.2 | 32.9 | — |
| Diluted Weighted Avg Shares | 57.4 | 57.6 | 55.0 | 44.0 | 36.3 | 36.2 | 32.9 | — |
| Supplemental | ||||||||
| EBIT | (51.9) | 12.5 | (78.8) | (86.5) | (92.8) | (126.9) | (69.6) | (29.3) |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.